Nicola Fusco, Director of Biobank for Translational and Digital Medicine Unit, Laboratory of Pathological Anatomy (Histology and NGS Molecular Diagnostics), and Division of Pathology at IEO European Institute of Oncology, shared a post on LinkedIn:
“Excited to share our new article “Inter-Assay Variability of TROP2 IHC in Triple-Negative Breast Cancer”, just published in Molecular Diagnosis and Therapy Springer Nature.
Our findings highlight a key challenge: traditional IHC assays for TROP2 show significant variability in TNBC, limiting their clinical application.
The way forward? AI-powered digital pathology. Novel approaches like Quantitative Continuous Scoring (QCS) can deliver reproducible, objective, and clinically meaningful biomarker assessment.
Proud of my team at IEO for driving this work at the interface of traditional pathology, AI, and oncology.”
Title: Inter-Assay Variability of TROP2 Immunohistochemistry in Triple-Negative Breast Cancer
Authors: Giulia Cursano, Alberto Concardi, Mariia Ivanova, Chiara Frascarelli, Eltjona Mane, Elisa Mangione, Stefano Santaguida, Daniela Tosoni, Salvatore Pece, Antonio Marra, Carmen Criscitiello, Giuseppe Curigliano, Giuseppe Viale, Konstantinos Venetis, Elena Guerini Rocco, Nicola Fusco
Read The Full Article at Springer Nature Link.
More posts featuring Nicola Fusco.